Cytosorbents Corp Quarterly Operating Lease, Payments in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Cytosorbents Corp quarterly/annual Operating Lease, Payments history and growth rate from Q1 2018 to Q3 2024.
  • Cytosorbents Corp Operating Lease, Payments for the quarter ending September 30, 2024 was $547K, a 13.6% decline year-over-year.
  • Cytosorbents Corp Operating Lease, Payments for the twelve months ending September 30, 2024 was $2.34M, a 10.5% decline year-over-year.
  • Cytosorbents Corp annual Operating Lease, Payments for 2023 was $2.4M, a 18.1% decline from 2022.
  • Cytosorbents Corp annual Operating Lease, Payments for 2022 was $2.94M, a 49.1% increase from 2021.
  • Cytosorbents Corp annual Operating Lease, Payments for 2021 was $1.97M, a 110% increase from 2020.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Quarterly (USD)
Operating Lease, Payments, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $2.34M $547K -$86K -13.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $2.42M $566K +$100K +21.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $2.32M $552K -$81K -12.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.4M $671K -$207K -23.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-15
Q3 2023 $2.61M $633K -$26K -3.95% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 $2.64M $466K -$219K -32% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $2.86M $633K -$80K -11.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $2.94M $878K +$164K +22.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-15
Q3 2022 $2.77M $659K +$66K +11.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $2.71M $685K +$255K +59.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 $2.45M $713K +$482K +209% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $1.97M $714K +$435K +156% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-15
Q3 2021 $1.53M $593K +$382K +181% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $1.15M $430K +$217K +102% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $934K $231K -$3.14K -1.34% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $937K $279K +$52K +22.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-09
Q3 2020 $885K $211K -$23K -9.83% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $908K $213K -$17K -7.39% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $925K $234K +$19K +8.84% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $906K $227K +$32K +16.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-10
Q3 2019 $874K $234K +$19K +8.84% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $855K $230K +$34K +17.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $821K $215K +$16K +8.04% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $805K $195K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-09
Q3 2018 $215K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $196K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $199K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.